ELTX
$12.18
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II cl...
Recent News
Elicio Therapeutics: Q4 Earnings Snapshot
BOSTON (AP) — Elicio Therapeutics, Inc. ELTX) on Thursday reported a loss of $7.7 million in its fourth quarter. The Boston-based company said it had a loss of 49 cents per share.
While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownership
Key Insights Elicio Therapeutics' significant individual investors ownership suggests that the key decisions are...
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
Elicio Therapeutics (ELTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Elicio Therapeutics: Q3 Earnings Snapshot
BOSTON (AP) — Elicio Therapeutics, Inc. ELTX) on Thursday reported a loss of $10.1 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of 60 cents.
Elicio’s peptide cancer vaccine shows survival benefit in Phase I trial
The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune cells.